Coya Therapeutics stock maintained at Buy by H.C. Wainwright

Coya Therapeutics enrolled its 100th patient in the 120-participant Phase 2/3 ALSTARS trial of COYA 302 for ALS, with full enrollment expected in coming weeks and top-line data due in early Q2 2027. H.C. Wainwright reiterated its Buy rating and $18 price target versus Coya's $5.18 share price, implying substantial upside. The clinical-stage biotech has liquid assets exceeding short-term obligations and more cash than debt, supporting trial funding, while shares have risen nearly 6% in a week and 23% over six months.

Analysis

The relevant valuation change is not enrollment itself but the reduction in execution risk before a 2027 binary readout. With roughly 40 patients per arm across two dose cohorts and placebo, the trial has limited tolerance for endpoint variability, missing data, or an uneven placebo decline rate; a statistically ambiguous result is a meaningful probability even if the mechanism is biologically active. The analyst target should not be treated as price discovery: it is highly sensitive to assumed probability of success, peak penetration, and dilution, none of which enrollment progress validates.

Near term (days to 3 months), completion of enrollment can support a modest de-risking rerating, particularly in a thin-float clinical-stage name, but it does not create a fundamental catalyst commensurate with the implied target upside. Over 6-18 months, the dominant variable is cash runway through database lock and topline data. A cash balance exceeding debt is insufficient evidence of runway; investors need quarterly operating cash burn, trial-cost accruals, and any ATM/shelf capacity to assess whether equity issuance becomes the effective financing event before efficacy data.

The key contradiction is the reported enrollment timeline: completion 'within weeks' versus a later-2026 expectation. This should be resolved directly with management because it affects both data-readout confidence and the expected duration of cash consumption. Falsification of a constructive pre-readout view would be a delayed completion update, material increase in R&D burn, an ATM draw, or guidance that moves topline data beyond Q2 2027.

Key Decisions for Investors

• Maintain COYA as a watch-list biotech catalyst rather than initiate a core directional position before confirmation of full enrollment and cash runway; reassess after the next 10-Q for quarterly burn, cash balance, and financing instruments.
• If enrollment is formally completed on the near-term timeline and disclosed cash funds operations through at least Q2 2027 without a near-term raise, consider a small long COYA position sized as a binary-event exposure, not a fundamental compounder; cap risk at 25-35% downside from entry given probable financing and endpoint-volatility risk.
• Do not use the $18 analyst target as an entry anchor. Add only if the company provides credible statistical assumptions for the ALSFRS-R endpoint and confirms that the two-dose design retains adequate power after attrition.
• Set an alert for any delay in enrollment completion or a financing filing: either event would likely compress the pre-readout multiple and is a reason to avoid or reduce exposure rather than average down.